Baxter (NYSE:BAX) said today that it closed its $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz. According to the deal, Baxter gains Claris’ portfolio of injectable generics and three manufacturing plants. The Deerfield, Ill.-based company said it plans to add new aseptic manufacturing and lyophilization capabilities, as well as invest in new technology platforms, […]
Claris Lifesciences
FTC approves Baxter’s $625m Claris buyout, with conditions
The Federal Trade Commission approved Baxter‘s (NYSE:BAX) $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz, but mandated that the companies divest two drugs products – an antifungal agent, fluconazole, and intravenous milrinone. The FTC filed a complaint saying that the original deal would likely reduce competition in the U.S. for fluconazole since Baxter […]
Baxter to put up $625m for Claris Injectables generics biz
Baxter (NYSE:BAX) said today that acquired Claris Lifesciences (BOM:533288) subsidiary Claris Injectables for $625 million. The deal is expected to close in the 2nd half of next year. Deerfield, Ill.-based Baxter said it plans to pay for the acquisition with cash on hand, debt or a combination. Baxter anticipates launching 7 to 9 new products […]